Lonza’s Capsule Delivery Solutions, part of Lonza Pharma & Biotech, is launching Capsugel Vcaps Gen C, a high-quality capsule based on a carrageenan gelling-agent formulation. The new entry expands the Lonza Capsugel hydroxypropyl methyl cellulose (HPMC) portfolio.
The launch of the high-performing, gelling agent-based capsule is the first since Lonza’s acquisition of Capsugel and part of the company’s business strategy to drive growth, according to Teun Van der Heide, head of Capsule Delivery Solutions at Lonza.
“The new HPMC formulation of Vcaps Gen C meets the demand of pharmaceutical manufacturers for a fast-dissolving, non-animal capsule that is robust and offers a high-performance machinability,” Stef Vanquickenborne, head of R&D at the capsule delivery unit, said.
Capsugel-brand specialty HPMC products include Vcaps Plus and Vcaps Enteric. The addition of Vcaps Gen C broadens the company’s HPMC product portfolio, which provides solutions for immediate and modified release dosage forms, and aims to help pharmaceutical customers bring products to market more quickly and reliably, according to Lonza.
(Source: Lonza Pharma & Biotech)
